In the videos below, four T2EVOLVE consortium members introduce themselves, explain why T2EVOLVE is important to them, discuss projects they are working on and what patients can expect from this, and explain a bit more about CAR T-cell treatment in Europe.
In this video, Prof Dr Michael Hudecek, clinician scientist at the University Hospital of Würzburg, Germany, T2EVOLVE Project Coordinator and Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, introduces himself and talks amongst others about the current status of CAR T-cell therapy for treatment of patients with multiple myeloma and why it is important to participate in a clinical trial.
In this video, Prof Dr Ulrich Jäger, hematologist at the Medical University of Vienna and Head of the clinical department for hematology and hemostaseology at Vienna General Hospital, Vienna, Austria, introduces himself and talks about the current indications for commercially available CAR T-cell therapy, reasons for not being eligible for CAR T-cell therapy if you have the correct indication, and how T2EVOLVE helps with the development of this new treatment.
Maria José Kersten
In this video, Prof Dr Marie José Kersten, hematologist at Amsterdam University Medical Centers and co-founder of LYMMCARE (Lymphoma and Myeloma Center Amsterdam) and the Dutch LLPC consortium which is focused on performing early clinical studies in the Netherlands, introduces herself and talks amongst others about quality of life and long-term toxicity (side effects) after CAR T-cell therapy.
In this video, Elise Pennings, PhD student at Amsterdam University Medical Centers and Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands, introduces herself and talks about the current situation regarding access to CAR T-cell therapy in Europe and how patients can get involved in the T2EVOLVE project.